PEAR-TNBC

Indication: Early triple negative breast cancer

Location: United Kingdom (see below for sites)

Type: Observational

Protocol (please note, this may not be upto date, and should not be used by trial sites)

Background:

Triple negative breast cancer (TNBC) is a type of breast cancer that lacks receptors for oestrogen and progesterone hormones and the HER2 protein. To treat TNBC, combination chemotherapies are required. This is administered prior to surgery (known as neoadjuvant chemotherapy).

Approximately 40% of patients with TNBC who receive chemotherapy before their surgery (neoadjuvant) achieve pathological complete response at surgery (pCR). This means that there is no sign or evidence of cancer in the breast tissue removed during surgery. There is a strong link between achieving pCR at surgery and long-term outcome. It is therefore important to develop new treatment strategies that can improve pCR in patients with TNBC.

Description:

This observational study is recruiting up to 60 patients with early TNBC that are eligible for neoadjuvant chemotherapy followed by surgery. Patients are expected to attend an additional procedure to remove a small piece of tumour using a core needle biopsy. This tumour will be used for analysis on Pear’s system to determine the likelihood of response to a given chemotherapy regimen. As this is an observational study, the results will not be shared with your oncologist at the time of initial treatment, and you will be treated using the standard of care. The goal of the study is to establish the accuracy of Pear’s test at predicting pathological complete response to help guide future patients to better treatments.

If you are interested in enrolling, please contact your doctor about whether you are eligible.

For more information, contact trials@pearbio.com

Open Sites & Investigators:

Bart’s Hospital, London (Lead site): Dr. Peter Hall

Wythenshawe Hospital, Manchester: Dr. Cliona Kirwan

North Manchester General Hospital: Dr. Absar Mohammed

Royal Marsden Hospital: Dr. Marios Tasoulis

Imperial College Healthcare NHS Trust: Dr. Suzy Cleator